摘要
目的探讨治疗前外周血炎性指标在三阴性乳腺癌(triple negative breast cancer,TNBC)新辅助化疗(NAC)中的作用及其与临床病理因素的关系。方法根据ROC曲线,制定外周血炎性指标临界值,对比化疗前不同外周血炎性指标与化疗后病理完全缓解(pCR)率及临床病理因素的关系。结果中性粒细胞计数与TNBC患者的年龄、Ki67、脉管癌栓、肿瘤大小、淋巴结转移状况密切相关;淋巴细胞(ALC)低组较高组的患者肿瘤分级越高,直径越大,淋巴结转移数目越多;高中性粒细胞计数/淋巴细胞计数(NLR)组的患者较低NLR组的患者更年轻,Ki67更高,淋巴结转移个数更多,且具有脉管癌栓的人数更多;高ALC组与低NLR组与对照组相比均表现出较高的pCR率。结论首次证实了TNBC患者NAC后高淋巴细胞计数、低NLR与pCR的统计学相关性,并提示了治疗前外周血炎性细胞计数的预测价值。
Objective To assess the correlation between peripheral inflammation/immune biomarkers preoperative and clinical pathological factors in neoadjuvant chemotherapy(NAC)patients with triple negative breast cancer(TNBC).Methods The critical value of peripheral inflammation/immune biomarkers was established according to ROC curve,and the relationship between clinical pathological facters and pCR rate after NAC was compared.Results Neutrophilic granulocyte count was closely related to the patients age,Ki67,vasculature,tumor size and lymph node metastasis of patients with TNBC.Patients in lower lymphocyte count group with higher tumor grade,larger diameter and more number of lymph node metastases compared with higher lymphocyte count group.The number of lymph node metastases of patients in the high neutrophil-to-lymphocyteratiol(NLR)group was significantly higher than that in the low NLR group,the patients in the high NLR group were younger,the Ki67 was higher,and the number of patients with vascularized cancer was higher.The high lymphocyte group and the low NLR group showed higher pCR rate than the control group.Conclusion It is first confirmed that high lymphocyte count and low NLR are related to pCR rate in TNBC after NAC.The predictive value of peripheral inflammation/immune biomarkers before treatment is suggested.
作者
关伟
张东伟
GUAN Wei;ZHANG Dong-wei(Department of Inspection,The Seventh People’s Hospital of Changzhou City,Changzhou213000,China;Department of Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China)
出处
《哈尔滨医科大学学报》
CAS
2019年第1期80-83,共4页
Journal of Harbin Medical University
基金
黑龙江省院科技合作项目(YS17C22)
关键词
三阴乳腺癌
新辅助化疗
外周血炎性指标
病理完全缓解
triple negative breast cancer
neoadjuvant chemotherapy
peripheral inflammation/immune biomarkers
pathological complate response
